Weight Loss & Comorbidity Resolution With LAGB Alone vs. LAGB With Gastric Plication

Sponsor
Northwell Health (Other)
Overall Status
Completed
CT.gov ID
NCT01703546
Collaborator
(none)
420
2
1
48
210
4.4

Study Details

Study Description

Brief Summary

The purpose of this research study is to evaluate whether combining laparoscopic adjustable gastric band (AKA: lap-band surgery, LAGB) and laparoscopic gastric plication (making tucks in the large curve of the stomach with stitches) to lap-band surgery alone will result in a greater loss of excess weight over time. We anticipate that the average percent of excess body weight loss for study subjects will exceed 29% at 12 months.

Condition or Disease Intervention/Treatment Phase
  • Procedure: LAGB & LGCP
N/A

Detailed Description

Laparoscopic Adjustable Gastric Banding when combined with gastric plication will provide lasting weight loss benefits to patients. We are projecting that the percent of Excess Body Weight Loss (% EWL) will be greater in study subjects when compared with our control group with LAGB alone. Furthermore, it is anticipated that the % EWL in study subjects will be similar to patients who have laparoscopic Roux-En-Y Gastric Bypass.

Study Design

Study Type:
Interventional
Actual Enrollment :
420 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Weight Loss & CoMorbidity Resolution With Laparoscopic Adjustable Gastric Band Alone vs. Laparoscopic Adjustable Gastric Band With Gastric Plication
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: LAGB & LGCP

All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP). The percent of Excess Body Weight Loss will be monitored at all post op visits.

Procedure: LAGB & LGCP
All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
Other Names:
  • Laparoscopic Adjustable Gastric Band & Gastric Plication
  • Outcome Measures

    Primary Outcome Measures

    1. % Excess Body Weight Loss (%EWL) [6 months post procedure]

      Excess Body Weight is identified pre-operatively and will be monitored during each post operative visit. The percent of Excess Body Weight Loss (%EWL) will be calculated using as a baseline the % Excess Body Weight identified pre-operatively during the subject's initial consult. The change in %EWL at will be calculated at 6 months and 12 months. The %EWL will then be compared to a similar cohort of patients who had the LAGB alone at the same milestones. It is anticipated that study patients' %EWL will be significantly greater.

    Secondary Outcome Measures

    1. HgbA1c [12 months post procedure]

      A baseline HgbA1c will be obtained pre-operatively for study patients with a comorbid diagnosis of Type 2 Diabetes. HgbA1C will also be obtained at 6 months and 12 months to evaluate the change from the baseline HgbA1C.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Body Mass Index (BMI) > 35

    • Meet ASMBS and NIH criteria for Weight Loss Surgery

    • ASA Class I - III

    • Agree to refrain from any type of weight-loss drug (prescription or OTC)or elective procedure that would affect body weight for the duration of the trial.

    • English speaking & comprehension

    • Normal mental caliber.

    Exclusion Criteria:
    • Pregnancy, Liver failure or Kidney failure

    • Women of childbearing potential lactating at the time of initial consult or at the time of surgery

    • Any condition which precludes compliance with the study

    • History or presence of pre-existing autoimmune connective tissue disease or cancer must be evaluated on a case by case basis by the Director of Bariatric Surgery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Syosset Hospital - Center for Bariatric Surgical Specialties, 221 Jericho Turnpike Syosset New York United States 11791
    2 Syosset Hospital, Center for Bariatric Surgical Specialties Syosset New York United States 11791

    Sponsors and Collaborators

    • Northwell Health

    Investigators

    • Study Chair: Robert Ward, MD, North Shore LIJ Health System, Syosset Hospital, Director of Surgery
    • Principal Investigator: Allison Barrett, MD, North Shore LIJ Health System Syosset Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Allison Barrett, Principal Investigator, Northwell Health
    ClinicalTrials.gov Identifier:
    NCT01703546
    Other Study ID Numbers:
    • 11-277A
    First Posted:
    Oct 10, 2012
    Last Update Posted:
    Jan 14, 2016
    Last Verified:
    Jan 1, 2016
    Keywords provided by Allison Barrett, Principal Investigator, Northwell Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 14, 2016